open access

Vol 18, No 3 (2013)
Reviews
Published online: 2013-05-01
Submitted: 2012-09-07
Get Citation

Prognostic factors and survival in metastatic breast cancer: A single institution experience

Afef Khanfir, Faiez Lahiani, Racem Bouzguenda, Ines Ayedi, Jamel Daoud, Mounir Frikha
DOI: 10.1016/j.rpor.2013.01.001
·
Rep Pract Oncol Radiother 2013;18(3):127-132.

open access

Vol 18, No 3 (2013)
Reviews
Published online: 2013-05-01
Submitted: 2012-09-07

Abstract

Background

The current retrospective study aims to identify some determinants of survival in metastatic breast cancer.

Methods

The study concerned 332 patients with synchronous (SM) or metachronous (MM) metastatic breast cancer treated between January 2000 and December 2007. Statistical comparison between subgroups of patients concerning survival was carried out employing log-rank test for the invariable analysis and Cox model for the multivariable analysis. Factors included: age group (≤50 years vs. >50; ≤70 years vs. >70; ≤35 years vs. >35), menopausal status, presentation of metastatic disease (SM vs. MM), disease free interval (DFI) (≤24 months vs. >24 months; ≤60 months vs. >60 months), performance status at diagnosis of metastatic disease (PS) (0–1 vs. >1), hormone receptors (HR), number of metastatic sites (1 site vs. >1), nature of the metastatic site (visceral vs. non visceral), first line therapy, surgery of the primary tumor (SPT), locoregional radiotherapy (LRRT) and use or not of bisphosphonates.

Results

Overall survival at 5 years was 12%. Positive prognostic factors in univariate analysis were: age[[ce:hsp sp="0.25"/]]≤[[ce:hsp sp="0.25"/]]70 years, hormono-dependence of the tumor, good PS (PS 0–1), less than two metastatic sites, no visceral metastases, DFI[[ce:hsp sp="0.25"/]]≥[[ce:hsp sp="0.25"/]]24 months, SPT or LRRT. In multivariate analysis, favorable independent prognostic factors included: good PS (PS 0–1), absence of visceral metastases (liver, lung, brain) and age[[ce:hsp sp="0.25"/]]≤[[ce:hsp sp="0.25"/]]70 years.

Conclusion

Many of the prognostic factors in metastatic breast cancer found in our study are known in the literature but some of them, like the application of locoregional treatment (radiotherapy or surgery) and the use of bisphosphonates, need to be further investigated in randomized clinical trials.

Abstract

Background

The current retrospective study aims to identify some determinants of survival in metastatic breast cancer.

Methods

The study concerned 332 patients with synchronous (SM) or metachronous (MM) metastatic breast cancer treated between January 2000 and December 2007. Statistical comparison between subgroups of patients concerning survival was carried out employing log-rank test for the invariable analysis and Cox model for the multivariable analysis. Factors included: age group (≤50 years vs. >50; ≤70 years vs. >70; ≤35 years vs. >35), menopausal status, presentation of metastatic disease (SM vs. MM), disease free interval (DFI) (≤24 months vs. >24 months; ≤60 months vs. >60 months), performance status at diagnosis of metastatic disease (PS) (0–1 vs. >1), hormone receptors (HR), number of metastatic sites (1 site vs. >1), nature of the metastatic site (visceral vs. non visceral), first line therapy, surgery of the primary tumor (SPT), locoregional radiotherapy (LRRT) and use or not of bisphosphonates.

Results

Overall survival at 5 years was 12%. Positive prognostic factors in univariate analysis were: age[[ce:hsp sp="0.25"/]]≤[[ce:hsp sp="0.25"/]]70 years, hormono-dependence of the tumor, good PS (PS 0–1), less than two metastatic sites, no visceral metastases, DFI[[ce:hsp sp="0.25"/]]≥[[ce:hsp sp="0.25"/]]24 months, SPT or LRRT. In multivariate analysis, favorable independent prognostic factors included: good PS (PS 0–1), absence of visceral metastases (liver, lung, brain) and age[[ce:hsp sp="0.25"/]]≤[[ce:hsp sp="0.25"/]]70 years.

Conclusion

Many of the prognostic factors in metastatic breast cancer found in our study are known in the literature but some of them, like the application of locoregional treatment (radiotherapy or surgery) and the use of bisphosphonates, need to be further investigated in randomized clinical trials.

Get Citation

Keywords

Breast cancer; Metastasis; Prognostic factors; Survival

About this article
Title

Prognostic factors and survival in metastatic breast cancer: A single institution experience

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 18, No 3 (2013)

Pages

127-132

Published online

2013-05-01

DOI

10.1016/j.rpor.2013.01.001

Bibliographic record

Rep Pract Oncol Radiother 2013;18(3):127-132.

Keywords

Breast cancer
Metastasis
Prognostic factors
Survival

Authors

Afef Khanfir
Faiez Lahiani
Racem Bouzguenda
Ines Ayedi
Jamel Daoud
Mounir Frikha

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl